H ypertrophic growth and remodeling of the adult heart begin as normal compensatory responses to a variety of physiological and pathological stimuli including exercise, pregnancy, pressure overload, hypertension, myocardial infarction, and primary genetic abnormalities. [1] [2] [3] Prolonged hypertrophic response may eventually lead to heart failure and death. Pathological hypertrophy is often associated with structural and functional remodeling of the heart. Profound changes in gene expression during pathological cardiac hypertrophy are common, particularly in the case of genes that code for proteins involved in regulating contraction ion channels, for example. 4 Alterations of intracellular Ca 2ϩ handling could lead to abnormal Ca 2ϩ signaling cascades, a phenomenon that has been shown to contribute to the pathogenesis of cardiac hypertrophy and heart failure. 5, 6 However, the detailed mechanism of how the cardiac myocytes distinguish Ca 2ϩ transients that occur at every heartbeat from those meant to trigger intracellular hypertrophic signaling remains largely unknown. Intracellular Ca 2ϩ levels could be altered because of either changes in Ca 2ϩ release from intracellular organelles or the influx of extracellular Ca 2ϩ , and in both cases, this could be attributable to the activities of either ligand-or voltage-activated Ca 2ϩ channels. Indeed, ligand-activated Ca 2ϩ channels, such as store-operated Ca 2ϩ channels, have been implicated in the signaling pathway that leads to cardiac hypertrophy. 7 Candidate proteins for store-operated Ca 2ϩ channels, such as transient receptor potential proteins (including TRPC1, TRPC3, and TRPC6), have been shown to act as positive regulators of calcineurin/NFAT-mediated signaling, which drive cardiac hypertrophy both in vitro and in vivo. 8 -11 L-type Ca 2ϩ channels are the main voltage-activated Ca 2ϩ channels responsible for triggering Ca 2ϩ -induced Ca 2ϩ release during excitation-contraction coupling. Their role in the development of cardiac hypertrophy remains controversial. In general, the current density of L-type Ca 2ϩ channels is either unchanged or slightly elevated when hypertrophy is mild and slightly reduced when hypertrophy is severe. [12] [13] [14] Although normally expressed during developmental stages and not expressed in adult cardiac myocytes, T-channels are reexpressed after development of pathological hypertrophy, in the postinfarction heart, and during stimulation with certain hormones. [15] [16] [17] [18] [19] [20] [21] [22] [23] The pore-forming subunits of T-channels are encoded by 3 genes, Ca v 3.1, -3.2 and -3.3, 24 -26 and both Ca v 3.1 and Ca v 3.2 are present in cardiac tissue. [27] [28] [29] Mice lacking Ca v 3.1 T-channels display abnormal sinoatrial node pacemaker activity and atrioventricular conduction, 30 whereas mice lacking Ca v 3.2 exhibit recurrent coronary vasospasms. 31 Ca v 3.1 and Ca v 3.2 have been reported to be upregulated in various animal models following cardiac hypertrophy. 18, 19, 22 However, the physiological role of T-channel reexpression under these conditions is unclear.
In this study, we aimed to determine whether Ca v 3.2 T-channels are involved in the development of pathological cardiac hypertrophy and whether the calcineurin-NFAT pathway is downstream of Ca v 3.2 T-channels during cardiac hypertrophy. Using Ca v 3.2 Ϫ/Ϫ and Ca v 3.1 Ϫ/Ϫ mice, we show that Ca v 3.2 but not Ca v 3.1 T-channels are required for the development of cardiac hypertrophy induced either by pressure overload and angiotensin (Ang) II treatment in vivo and in vitro. We also discover that the T-channel blocker ethosuximide could prevent the development of pressure overload-induced cardiac hypertrophy in wild-type (WT) mice, and that the stimulation of NFAT signaling in response to pressure overload requires the presence of Ca v 3.2. Overall, our results demonstrate that Ca v 3.2 T-channels regulate pathogenic cardiac hypertrophy in vivo by activating the calcineurin-NFAT signaling cascade.
Materials and Methods
Animals were kept under specific pathogen-free conditions, and all procedures performed were approved by the Institutional Animal Care and Use Committee of Academia Sinica, Taiwan. An expanded Materials and Methods section detailing the methods and protocols used in the present study is available in the online data supplement at http://circres.ahajournals.org. Table I ), thus resulting in a higher ratio of heart weight/body weight (HW/BW) (in milligrams per gram) ( Figure 1A and supplemental Table I ). In WT and Ca v 3.1 Ϫ/Ϫ mice, by 2 weeks following transverse aortic banding (TAB) treatment, the HW/BW ratio had increased significantly by 39.9% and 22.9%, respectively, relative to that in age-matched, sham-operated WT and Ca v 3.1 Ϫ/Ϫ mice (PϽ0.001). In Ca v 3.2 Ϫ/Ϫ mice, by contrast, the HW/BW ratio in the banded animals and their sham controls did not differ significantly (Pϭ0.07) ( Figure 1A ). Measurement and comparison of another hypertrophy index, the HW/tibial length (in milligrams per millimeter) ratio, across groups yielded similar results ( Figure 1B ). We also measured the blood pressure of WT and Ca v 3.2 Ϫ/Ϫ mice at both basal and 2 weeks after TAB. There is no significant difference in blood pressure between WT and Ca v 3.2 Ϫ/Ϫ mice after TAB (109Ϯ3 for WT versus 109Ϯ2 mm Hg for Ca v 3.2 Ϫ/Ϫ ). Histological examination of hearts also showed a significant increase in ventricular wall thickness in the banded WT mice but less in the banded Ca v 3.2 Ϫ/Ϫ mice ( Figure 2A ). One hallmark of cardiac hypertrophy is the enlargement of individual myocytes, and thus cardiomyocyte hypertrophy was also assessed at the cellular level. TAB treatment was found to lead to a significant increase in the cardiac myocyte cross-sectional diameter (in microns) by 23% in banded WT mice compared with sham-operated controls (PϽ0.001) (Figure 2B ). In contrast, there was no significant change in the myocyte cross-sectional diameter from the banded Ca v 3.2 Ϫ/Ϫ mice compared with the sham-operated controls (Pϭ0.1). The progression to the cardiomyopathy is accompanied by increased fibrosis. Ca v 3.2 Ϫ/Ϫ mice have been shown to display focal myocardial fibrosis caused by abnormal coronary function. 31 Indeed, there was more fibrosis in sham- operated Ca v 3.2 Ϫ/Ϫ mice than those in WT mice ( Figure 2C ). After TAB treatment, there was a marked increase in myocardial fibrosis in both WT and Ca v 3.2 Ϫ/Ϫ mice, and no significant difference in myocardial fibrosis between WT and Ca v 3.2 Ϫ/Ϫ mice was observed after TAB ( Figure 2A and 2C). Because cardiac hypertrophy is frequently accompanied by a reexpression of the cardiac fetal genes, we examined the expression of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), ␣-myosin heavy chain (␣-MHC), ␤-myosin heavy chain (␤-MHC), and skeletal ␣-actin (␣-SA) in the banded WT and Ca v 3.2 Ϫ/Ϫ hearts using real-time quantitative PCR. As expected, ANF, BNP, ␤-MHC, and ␣-SA were significantly upregulated in the banded WT heart, whereas ␣-MHC was downregulated ( Figure 2D ). Notably, despite the attenuation of hypertrophy in the Ca v 3.2 Ϫ/Ϫ heart, the expression of ANF, BNP, ␤-MHC, and ␣-SA were also upregulated and the expression of ␣-MHC was downregulated under these conditions (PϽ0.05), suggesting that Ca v 3.2 channels are not involved in the reexpression of these fetal genes during pathological hypertrophy.
Results

Impaired
We also performed serial echocardiography to characterize the change in cardiac structure and function after pressure overload. Left ventricle mass (LVM) and the LVM/BW ratio had increased significantly in the banded WT and Ca v 3.1 Ϫ/Ϫ mice at 2 and 4 weeks after banding relative to animals at basal condition. In Ca v 3.2 Ϫ/Ϫ mice, however, LVM and the LVM/BW ratio did not increase at all in 2-week banded Ca v 3.2 Ϫ/Ϫ mice, although a modest but significant increase in LVM/BW was observed at 4 weeks after banding ( Figure 3A and 3B and supplemental Table I ). The hypertrophic response in banded Ca v 3.2 Ϫ/Ϫ mice was markedly reduced compared to that in banded WT animals for the same period, whereas hypertrophic response in banded Ca v 3.1 Ϫ/Ϫ mice was comparable to that in banded WT animals ( Figure 3B mice, although having a compromised vascular function, remain functionally intact in response to Ang II-induced hypertension ( Figure 4A ). As in the case of the TAB results, Ang II treatment led to a significant increase in the LVM/BW in WT but not in Ca v 3.2 Ϫ/Ϫ mice ( Figure 4B ). After 2 weeks of Ang II treatment, the ratio of LVM/BW increased significantly by 33.6% in WT mice (PϽ0.01), whereas the ratio did not change significantly in Ca v 3. 
Inhibition of T-type Ca 2؉ Channels Blunts Cardiac Hypertrophy
Because pressure overload-and Ang II-induced cardiac hypertrophy was blunted in Ca v 3.2 Ϫ/Ϫ mice, we tested whether cardiac hypertrophy could be inhibited by blocking T-channels. Because no specific T-channel blocker is available commercially, we chose ethosuximide, which has been used to block T-channels in vitro and in vivo, [32] [33] [34] to test our hypothesis. WT mice were subjected to TAB and concurrently infused with ethosuximide for 2 weeks. As shown in Figure 6A , TAB-induced cardiac hypertrophy (as assessed by the LVM/BW ratio) was significantly attenuated in the ethosuximide-treated groups by 15.6% (PϽ0.01), when compared to the corresponding vehicle-treated group. We also found that ethosuximide can reduce Ang II-mediated increase of LVM/BW ratio by 19% (PϽ0.05) ( Figure 6B ). These data demonstrate that blocking T-channels in WT mice can reduce cardiac hypertrophy induced by either pressure overload or treatment with Ang II.
Electrophysiological Examinations of Ca
2؉
Currents From Acutely Isolated Left Ventricular Myocytes
Reappearance of the T-current has been observed in hypertrophied ventricular cells in the association with pressure overload in feline 16 and rat. 18, 19 Using the whole-cell patch-clamp technique, we examined whether T-type Ca 2ϩ current (T-current) reappeared in the left ventricular myocytes from 2-week TAB WT mice. Small but detectable T-currents were recorded in WT myocytes after TAB, whereas they are not detectable or very small in WT myocytes following sham operation ( Figure 7 ) (at Ϫ40 mV, Ϫ0.64Ϯ0.17 pA/pF for TAB [nϭ5] and Ϫ0.11Ϯ0.02 pA/pF for sham [nϭ12]; PϽ0.05). The T-current recorded in WT myocytes after TAB was peaked at approximately Ϫ40 mV, and bath application of 100 mol/L Ni 2ϩ caused a rapid reduction of T-current amplitude to Ϸ75% of control, indicating relatively high sensitivity of the current to Ni 2ϩ ( Figure 7B , inset). The L-type Ca 2ϩ current (L-current) density was similar in sham-operated WT myocytes compared Figure 7C ). It has been reported that the reduction of the L-current by continuous infusion of L-channel blocker 35 or the knockdown of L-channel accessory ␤ subunit 36 channels that open at the resting membrane potential of a HEK293 cell (ie, window current). 37, 38 As shown in Figure 8A , 10 mmol/L Ca 2ϩ significantly increased the NFAT-luciferase reporter activity relative to that of cells transfected with control vehicle and T-channel blocker mibefradil effectively blocked NFAT-luciferase activity triggered by calcium. We further investigated whether calcineurin-NFAT signaling is intact in the Ca v 3.2 Ϫ/Ϫ heart by crossing the Ca v 3.2 Ϫ/Ϫ mice with a NFATluciferase (Luc) reporter transgenic mice. 39 The basal level of NFAT-Luc reporter activity in the left ventricle was not significantly different between WT/NFAT-Luc and Ca v 3.2 Ϫ/Ϫ / NFAT-Luc mice ( Figure 8B ). As expected, cardiac NFAT-Luc reporter activity increased significantly by 2.5-fold (PϽ0.001) 2 weeks after TAB in the WT/NFAT-Luc mice. In contrast, there Figure 8C ). These data suggest that Ca v 3.2 channels are important in the activation of calcineurin-NFAT signaling and that the lack of NFAT-luciferase activity in the Ca v 3.2 Ϫ/Ϫ / NFAT-Luc mice is not attributable to a secondary change in the level of calcineurin A protein. To determine whether there could be any interaction between Ca v 3.2 T-channels and calcineurin, we performed coimmunoprecipitation experiments in vitro. We coexpressed vectors containing FLAGCa v 3.2 or FLAG-Ca v 3.1 and calcineurin in HEK293 cells. As shown in Figure 8D , calcineurin can be coimmunoprecipitated with FLAG-Ca v 3.2. In contrast, there is no detectable calcineurin in the FLAG vector control and a much weaker band of calcineurin coimmunoprecipitated with FLAGCa v 3.1 despite a larger amount of FLAG-Ca v 3.1 in the input lysates. The results suggest that the Ca v 3.2 T-channels can interact with calcineurin in HEK293 cells in vitro and could play a role in the hypertrophic signaling.
Discussion
Although T-type Ca 2ϩ channels have been previously implicated in the growth of cardiac tissues and in the pathogenesis associated with Ca 2ϩ overload and cardiomyopathy-related arrhythmias, 16 -23 little is known about the mechanism whereby these channels act. Using Ca v 3.2 Ϫ/Ϫ and Ca v 3.1 Ϫ/Ϫ mice, we were able to demonstrate that Ca v 3.2 T-channels are required for hypertrophic response to mechanical stress and Ang II infusion. Upregulation of Ca v 3.1 mRNA was observed in hypertrophied ventricles and failure-stage hearts in rats. 19, 22 Paradoxically, in the hypertrophied rat hearts, the increased T-type calcium currents from left ventricular myocytes showed relatively high nickel sensitivity, a feature peculiar to Ca v 3.2 channel-generated currents. 18 A recent study reported that, in the ventricular septum of the aortic banded mouse heart, Ca v 3.1 mRNA expression decreased, whereas Ca v 3.2 mRNA expression was comparable to that in sham-operated control hearts. 40 These conflicting results may reflect the different genetic backgrounds of experimental animals and the surgical protocols whereby cardiac hypertrophy was induced. Never- theless, these studies failed to clarify whether the reexpression of T-channels is the consequence of cardiac remodeling in pathological states or whether the reexpressed T-channels, instead, initiate cardiac remodeling. Our demonstrations that nickel sensitive T-currents reappear in WT mice after TAB and T-channel blocker ethosuximide can blunt the development of cardiac hypertrophy induced by pressure overload or Ang II in WT animals suggest that Ca v 3.2 T-channels are indeed important in the initiation of pressure overload-and Ang II-induced cardiac hypertrophy in mice.
Pathological cardiac hypertrophy is commonly accompanied by myocyte enlargement, activation of a fetal program of cardiac gene expression, and fibrosis. 5 Our findings that banded Ca v 3.2 Ϫ/Ϫ mice were resistant to cardiac hypertrophy but not fetal gene activation and fibrosis suggest that Ca v 3.2 is not necessary for these pathological features during cardiac remodeling on stress. There are several reports showing that reexpression of cardiac fetal genes is not associated with cardiac hypertrophy but rather with the pathological features. For example, SCN5A heterozygous mice show upregulation of ␤-MHC and ␣-SA with no hypertrophy. 41 Increased level of ANF expression is associated with tissue pathology but not necessary to the degree of cardiac hypertrophy. 42 Intriguingly in a genetic mouse model with a yellow fluorescent protein-␤-MHC fusion gene, reexpression of ␤-MHC has been found to occur predominantly in myocytes associated with regions with perivascular and interstitial fibrosis during hypertrophy. 43 The Ca 2ϩ /calmodulin serine/threonine protein phosphatase calcineurin plays a central role in the development of pathological cardiac hypertrophy. Our studies show that cardiac hypertrophy responses are impaired in Ca v 3.2 Ϫ/Ϫ mice, NFAT activity in these mice is blunted following 2-week TAB, and the T-currents reexpress in myocytes from banded WT mice, implying Ca v 3.2 T-channels are also involved in the activation of calcineurin-NFAT signaling and essential for pathological cardiac hypertrophy. Although a proximal relationship among calcineurin-NFAT, Ca 2ϩ handling, and downstream effectors remains largely unclear, our coimmunoprecipitation work shows that the Ca v 3.2 T-channels could associate with calcineurin and thus play a role in the hypertrophic signaling. Several recent studies have demonstrated that TRPC1, TRPC3, and TRPC6 are involved in calcineurin/ NFAT activation and cardiac hypertrophy in rodent models. 8 -11 TRPC6 and TRPC3 transgenic mice exhibit cardiomyopathy associated with increased NFAT activity and with an increased susceptibility to stimulation by pressure overload. 8, 11 Furthermore, the promoter region of TRPC6 contains 2 NFAT binding sites, which suggests that positive feedback is involved in the regulation of the calcineurin-NFAT-TRPC6 signaling pathway. 11 We hypothesized that reexpressed Ca v 3.2 might induce cardiac hypertrophy by activating the calcineurin-NFAT pathway. Indeed, our analysis of mice harboring a transgenic NFAT-Luc reporter showed that blockers, kurtoxin and efonidipine, could prevent bovine serum-induced neonatal mouse cardiomyocyte hypertrophy through an inhibition of calcineurin-NFAT activation. 44 Interestingly, TRPC6 transcript levels have been reported to increase 3 weeks after TAB. 11 Moreover, following aortic banding in the rat, there is a 2-day delay in the association of calcineurin with calmodulin, 45 which coincides with the time point at which cardiac NFAT-Luc reporter activity is upregulated in mice. 39 This result suggests that calcineurin is activated as early as 2 days after stimulation. It is possible that hypertrophic stimuli lead to rapid activation of Ca v 3.2 channels, which then activate calcineurin-NFAT signaling at the initial stage of hypertrophic development, and that this, in turn, induces the sustained hypertrophic responses that are associated with TRPC channel upregulation.
In summary, in using a molecular genetic approach, we have demonstrated that Ca v 3.2 plays an important role in the development of cardiac hypertrophy induced by aortic banding and Ang II infusion and that Ca v 3.2 is required for activation of the calcineurin/NFAT pathway. The next steps in better understanding the development of cardiac hypertrophy include further evaluating the role of Ca v 3.2 inhibition in other genetic and acquired models of cardiac hypertrophy and identifying any Ca v 3.2-associated molecules that are involved in the regulation of cardiac hypertrophy.
Supplement Material
Materials and Methods
Animal Model of Cardiac Hypertrophy
Eight week-old adult male mice (C57BL/6, Ca V 3.1 -/-, Ca V 3.2 -/-or NFAT-luciferase reporter-transgenic) weighing 20-25g were subjected to pressure overload by transverse aortic banding (TAB) according to the method described previously 1 . The generation of Ca V 3.2 -/-and NFAT-luciferase reporter transgenic mice was also described previously 2, 3 .
Echocardiography and Blood Pressure Measurement
An ultrasound unit (ATL HDI 5000, SonoCT) with both a 15 MHz linear and a 7 -12
MHz sector transducer was used. The animals were anesthetized for echocardiographic examination using avertin (0. 
Real-time RT-PCR
Total RNA was extracted from lysates of left ventricle or cultured neonatal myocytes using Trizol reagent (Invitrogen Corp) according to the manufacturer's protocols. To assess mRNA transcript levels by real -time RT-PCR, the first-strand cDNA was first synthesized using the high capacity reverse transcriptase kit (Applied Biosystems) .
TaqMan primers and probes for hypertrophy marker genes, including mouse atrium natriuretic factor (ANF), brain natriuretic peptide (BNP), α -myosin heavy chain (α-MHC), β-myosin heavy chain (β -MHC) and skeletal α-actin (α-SA) and control GAPDH, were purchased from Applied Biosystems. Real-time PCR was performed using an ABI prism 7900 sequence detection system. The fluorescent amplification c urve of the product was determined, and the cycle at which the fluorescence reached a threshold was recorded (C t ) in triplicate and averaged. To control for variability in RNA quantity, the measured abundances of hypertrophic marker genes were normalized to that of GAPDH 
Chronic Drug Infusion Study
Drug delivery was achieved by implanting an osmot ic minipump (model 1002, Alzet, Durect; Cupertino, CA) subcutaneously under anesthesia by 1.5 % isoflurane (Halocarbon, River Edge, NJ). Ang II (1.3 mg/kg per day for 14 days) or saline (0.9 % NaCl) was infused continuously. For the hypertrophy preventio n study, pumps filled with ethosuximide (0.1 mg/kg/day) or vehicle were set to deliver immediately after TAB for 14 days.
Primary Culture of Newborn Mouse Cardiomyocytes
To isolate newborn cardiomyocyte, the ventricles from 1 -to 3-day-old WT and 
Statistical Analysis
Results are expressed as mean ± SEM. One way ANOVA repeated measurement (Turkey Test) or Student's t-test was used for comparison between basal data and the data with treatments at different time points within the same genotype . Kruskal-Wallis One
Way Analysis of Variance on Ranks (Dunn's Method, ANOVA) was used for comparison of the variants between groups with different genotype at the certain time poin t. A probability value < 0.05 was considered statistically significant.
